0001326110 2025-06-23 2025-06-23 0001326110 1 2025-06-23 2025-06-23 0001326110 2 2025-06-23 2025-06-23 _2:shares iso4217:USD shares iso4217:USD pure 0001326110 EX-FILING FEES S-8 S-8 ImmunityBio, Inc. false Equity CommonStock, par value $0.0001 per share true 46088027 2.8800 132733518 0.0001531 20321.5 false Equity CommonStock, par value $0.0001 per share true 32359674 2.8800 93195861 0.0001531 14268.29 225929379 34589.79 0 34589.79 <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”), this registration statement on Form S-8 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registration Statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) shall also cover any additional shares of the common stock, par value $0.0001 per share (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”), of ImmunityBio, Inc. (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) that become issuable with respect to the securities identified in the above table under the ImmunityBio, Inc. 2025 Equity Incentive Plan (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025 Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) by reason of any stock dividend, stock split, recapitalization, merger, consolidation or reorganization of or by us or similar transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of outstanding shares of Common Stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Represents 46,088,027 shares of Common Stock initially reserved for issuance pursuant to future awards under the 2025 Plan. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Represents up to an additional 32,359,674 shares of Common Stock that were subject to awards outstanding under the ImmunityBio, Inc. 2015 Equity Incentive Plan on the date of stockholder approval of the 2025 Plan and may be added to the 2025 Plan pursuant to Section 3(a)(ii) of the 2025 Plan if, following the the date of stockholder approval of the 2025 Plan, they expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Registrant for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to or repurchased by the Registrant due to failure to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act, solely for the purpose of calculating the registration fee based on the average of the high and low sales prices per share of Common Stock, as reported on the Nasdaq Global Select Market on June 20, 2025 (which is within five business days prior to the filing of this Registration Statement). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) Calculated at a rate of $153.10 per $1,000,000 of the proposed maximum aggregate offering price.</span></div> <div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”), this registration statement on Form S-8 (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registration Statement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) shall also cover any additional shares of the common stock, par value $0.0001 per share (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”), of ImmunityBio, Inc. (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) that become issuable with respect to the securities identified in the above table under the ImmunityBio, Inc. 2025 Equity Incentive Plan (the “</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025 Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">”) by reason of any stock dividend, stock split, recapitalization, merger, consolidation or reorganization of or by us or similar transaction effected without the Registrant’s receipt of consideration that results in an increase in the number of outstanding shares of Common Stock. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2) Represents 46,088,027 shares of Common Stock initially reserved for issuance pursuant to future awards under the 2025 Plan. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) Represents up to an additional 32,359,674 shares of Common Stock that were subject to awards outstanding under the ImmunityBio, Inc. 2015 Equity Incentive Plan on the date of stockholder approval of the 2025 Plan and may be added to the 2025 Plan pursuant to Section 3(a)(ii) of the 2025 Plan if, following the the date of stockholder approval of the 2025 Plan, they expire or otherwise terminate without having been exercised or issued in full, are tendered to or withheld by the Registrant for payment of an exercise price or for satisfying tax withholding obligations, or are forfeited to or repurchased by the Registrant due to failure to vest.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4) Estimated in accordance with Rules 457(c) and 457(h) of the Securities Act, solely for the purpose of calculating the registration fee based on the average of the high and low sales prices per share of Common Stock, as reported on the Nasdaq Global Select Market on June 20, 2025 (which is within five business days prior to the filing of this Registration Statement). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5) Calculated at a rate of $153.10 per $1,000,000 of the proposed maximum aggregate offering price.</span></div> 46088027 32359674